Intralesional Injection of Metronidazole for the Management of Cutaneous Leishmaniasis

Launched by HAYDER ADNAN FAWZI · Jan 27, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for cutaneous leishmaniasis, a skin infection caused by parasites. Researchers want to see how effective a local injection of metronidazole (a common antibiotic) is in treating this condition. In the trial, participants with one or more lesions (but fewer than seven) will receive weekly injections of metronidazole directly into their skin lesions for up to six weeks. Each lesion will be monitored for 90 days or until it heals.

To be eligible for this trial, participants must be between 6 and 75 years old and have single or multiple lesions of cutaneous leishmaniasis. However, those with weakened immune systems or allergies to the treatment cannot participate. Throughout the trial, patients will only need to come in for treatment and follow-up assessments to check on their lesions. This study aims to find a safe and effective way to help people recover from this skin infection.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with single or multiple (less than seven lesions) lesions of cutaneous leishmaniasis
• Exclusion Criteria:
• • Immunocompromised
• • Allergic reaction to treatment.